SEC Form 4														
FO	RM 4	D STAT	ES S	ECURITIES Washingt	SION]							
						,					OMB APPROVAL			
Section 16. Fo	c if no longer subject to rm 4 or Form 5 y continue. <i>See</i>).	pursuar	t to Section 16(a) of the Inv	of the Se	ecuritie	es Exchange A	-	Es	OMB Number: 3235-028 Estimated average burden hours per response: 0.5					
1. Name and Address of Reporting Person [*] <u>Kiener Peter A</u>					er Name and Ticke <u>Biopharma, I</u>					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)		3. Date 03/23	e of Earliest Transa /2023	ction (M	onth/[Day/Year)		Officer (give title Other (specify below) below)						
C/O CUE BIOPHARMA INC. 40 GUEST STREET					nendment, Date of	Original	Filed	(Month/Day/Y	6. Indi Line) X	- /				
(Street) BOSTON		Form filed by More than One Reporting Person												
(City)	(State)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	٦	able I - No	n-Deriva	tive S	ecurities Acq	uired,	Dis	posed of, o	or Ben	eficially	Owned			
····································			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Followir Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock				2023		М		9,682	A	\$2.86	9,682	D		
Common Stock	03/23/2023			S ⁽¹⁾		9,325	D	\$3.28(2)	357	D				

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$2.86	03/23/2023		М			9,682	(3)	03/23/2023	Common Stock	9,682	\$0.00	96,062	D	

Explanation of Responses:

1. Sale to cover exercise price of cashless exercise of stock option.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.20 to \$3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023.

Remarks:

/s/ Peter Kiener by Colin

Sandercock, attorney-in-fact

** Signature of Reporting Person

03/27/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.